TY - JOUR
T1 - Elevation of plasma and cerebrospinal fluid osteopontin levels in patients with atypical teratoid/rhabdoid tumor
AU - Kao, Chung Lan
AU - Chiou, Shih Hwa
AU - Ho, Donald Ming Tak
AU - Chen, Yann Jang
AU - Liu, Ren Shyan
AU - Lo, Chih Wen
AU - Tsai, Fu Ting
AU - Lin, Chi Hung
AU - Ku, Hung Hai
AU - Yu, Shang Ming
AU - Wong, Tai Tong
PY - 2005/2
Y1 - 2005/2
N2 - Osteopontin, a cancer metastasis-associated gene, is specifically up-regulated in central nervous system (CNS) atypical teratoid/rhabdoid tumor (AT/RT), but its biological behavior in the progression of CNS AT/RT has never been studied. We obtained plasma, cerebrospinal fluid (CSF), and brain tissue specimens from lobectomy of hemispherectomy samples from 39 patients (medulloblastoma, 16; AT/RT, 8; epilepsy, 6; hydrocephalus, 9). By enzyme-linked immunosorbent assay, the median osteopontin levels in plasma and CSF in AT/RT (852.0 and 1,175.0 ng/mL, respectively) were significantly higher than in medulloblastoma (492.5 and 524.5 ng/mL, respectively) and hydrocephalus and epilepsy (208.0 and 168.0 ng/mL, respectively) (P < .05). The results of real-time reverse transcriptase-polymerase chain reaction and immunohistochemical analysis demonstrated that osteopontin expression in AT/RT (n = 5) was significantly higher than in medulloblastoma (n = 8) samples. The differences in osteopontin expression in plasma, CSF, and tumor samples in AT/RT and medulloblastoma correlated with survival differences. In 5 patients with AT/RT, plasma osteopontin levels decreased after treatment but increased with relapse. Osteopontin might be a potential marker to aid in identifying AT/RT recurrence.
AB - Osteopontin, a cancer metastasis-associated gene, is specifically up-regulated in central nervous system (CNS) atypical teratoid/rhabdoid tumor (AT/RT), but its biological behavior in the progression of CNS AT/RT has never been studied. We obtained plasma, cerebrospinal fluid (CSF), and brain tissue specimens from lobectomy of hemispherectomy samples from 39 patients (medulloblastoma, 16; AT/RT, 8; epilepsy, 6; hydrocephalus, 9). By enzyme-linked immunosorbent assay, the median osteopontin levels in plasma and CSF in AT/RT (852.0 and 1,175.0 ng/mL, respectively) were significantly higher than in medulloblastoma (492.5 and 524.5 ng/mL, respectively) and hydrocephalus and epilepsy (208.0 and 168.0 ng/mL, respectively) (P < .05). The results of real-time reverse transcriptase-polymerase chain reaction and immunohistochemical analysis demonstrated that osteopontin expression in AT/RT (n = 5) was significantly higher than in medulloblastoma (n = 8) samples. The differences in osteopontin expression in plasma, CSF, and tumor samples in AT/RT and medulloblastoma correlated with survival differences. In 5 patients with AT/RT, plasma osteopontin levels decreased after treatment but increased with relapse. Osteopontin might be a potential marker to aid in identifying AT/RT recurrence.
KW - Atypical teratoid/rhabdoid tumor
KW - Medulloblastoma
KW - Osteopontin
KW - Primitive neuroectodermal tumor
UR - https://www.scopus.com/pages/publications/19944431379
UR - https://www.scopus.com/pages/publications/19944431379#tab=citedBy
U2 - 10.1309/0FTKBKVNK4T5P1L1
DO - 10.1309/0FTKBKVNK4T5P1L1
M3 - Article
C2 - 15842057
AN - SCOPUS:19944431379
SN - 0002-9173
VL - 123
SP - 297
EP - 304
JO - American Journal of Clinical Pathology
JF - American Journal of Clinical Pathology
IS - 2
ER -
